| Literature DB >> 16322789 |
David A D'Alessio1, Darleen A Sandoval, Randy J Seeley.
Abstract
Glucagon-like peptide-1 (GLP-1) has a diverse set of peripheral actions which all serve to promote enhanced glucose tolerance, and for this reason it has become the basis for new treatments for type 2 diabetes. In this issue of the JCI, Knauf et al. provide clear evidence that GLP-1 signaling in the CNS is also linked to the control of peripheral glucose homeostasis by inhibiting non-insulin-mediated glucose uptake by muscle and increasing insulin secretion from the pancreas. The authors' work points to an important need to integrate diverse GLP-1 signaling actions and peripheral GLP-1 function in order to better understand both normal and abnormal glucose homeostasis.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16322789 PMCID: PMC1297270 DOI: 10.1172/JCI27207
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808